Colorectal cancer is one of the most common cancers in the world, with over 1.4 million new cases diagnosed each year. Obtaining an early diagnosis is critical as it is currently one of the deadliest cancers, totaling more than 600,000 deaths each year.1,2
Existing cancer prevention and screening best practices can help in the early identification of CRC to provide patients more options and the best opportunity to get the treatment they need.
Roche is developing new diagnostic tests that will have a significant impact on disease management for cancer patients in the future. With a broad portfolio of tumor markers, as well as a range of molecular oncology tests, Roche will continue to be one of the leaders in providing cancer-focused treatments and diagnostics.
- WHO, IARC GLOBOCAN, Cancer Incidence and Mortality Worldwide in 2008 at http://globocan.iarc.fr/. Accessed June 1, 2016.
- Edwards BK, Ward E, Kohler BA, et al. Annual Report to the Nation on the Status of Cancer, 1975-2006, Featuring Colorectal Cancer Trends and Impact of Interventions (Risk Factors, Screening, and Treatment) to Reduce Future Rates. Cancer. 2009;116(3):544-573.